Cite this answer
Chonluten: quick citable summary
Chonluten is listed by PeptaHub as a immune peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Chonluten: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/chonluten. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/chonluten.
What is Chonluten?
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) bioregulator derived by Khavinson from bronchial epithelial cells. One in vitro study found it inhibits LPS-induced TNF in a human monocytic cell line. No lung-tissue, animal or human study of it could be located.
Overview
Chonluten is a synthetic tripeptide bioregulator (Glu-Asp-Gly, EDG) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and derived from bronchial epithelial cells. Its only located published result is anti-inflammatory activity in a human monocytic cell line. It is marketed for respiratory support, but no study of Chonluten in lung tissue, animals or humans could be located.
Mechanism of action
The one located study of Chonluten tested it in the human THP-1 monocytic cell line. There, the tripeptide inhibited tumor necrosis factor production by monocytes exposed to bacterial lipopolysaccharide, and along with the other Khavinson peptides tested it suppressed LPS-stimulated TNF and IL-6 expression in differentiated cells and reduced adhesion to activated endothelium. The authors read this as induction of TNF tolerance. The broader mechanism often attributed to Chonluten (nuclear translocation, minor-groove binding to lung-specific promoters, regulation of mucin, antioxidant and epithelial-barrier genes) is an extrapolation from the general Khavinson framework; no study measuring those endpoints for Chonluten was located.
Reported study ranges
No reported study ranges available yet.
Research summary
The evidence base for Chonluten is one in vitro paper. Avolio and colleagues (Int J Mol Sci 2022, with Khavinson as a co-author) tested Chonluten alongside Epitalon, Vilon, Thymogen and Thymalin in the human THP-1 monocytic cell line and found Chonluten inhibited LPS-induced TNF production. No animal study, no human study, and no lung-tissue study of Chonluten could be located in PubMed. Claims about restoring bronchial epithelial function in aged tissue, antioxidant gene modulation, or protection in pulmonary oxidative stress models have no located source and should not be treated as findings.[1]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Chonluten for synergistic effects.
Legal status
Not FDA-approved. Developed and studied in Russia; commercially available in Russia as a bronchopulmonary bioregulator supplement. Available in Western markets as a research chemical only.
Sourcing & access
Research compound
Chonluten is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Chonluten is a synthetic tripeptide (EDG) from the Khavinson bioregulator family, derived from bronchial epithelial cells and marketed for respiratory support. The only located published finding is anti-inflammatory activity in a cultured human monocytic cell line.
In the human THP-1 monocytic cell line, Chonluten inhibited TNF production by monocytes exposed to bacterial lipopolysaccharide, which the authors interpreted as induction of TNF tolerance. Claims that it binds lung-specific gene promoters or regulates mucin, antioxidant and epithelial-barrier genes are extrapolated from the general Khavinson peptide model and have not been measured for Chonluten.
Unknown. There are no published safety data for Chonluten in humans or animals. Mild injection site irritation is reported anecdotally. It is not FDA-approved.
There is no established dosing for Chonluten. No study in animals or humans has been published, so no dose, cycle length or route has been tested against an outcome. Figures circulating in supplier material are not traceable to a study and this page no longer lists them.